Please login to the form below

Not currently logged in
Email:
Password:

Valchlor

This page shows the latest Valchlor news and features for those working in and with pharma, biotech and healthcare.

EU nod for Actelion's skin cancer drug Ledaga

EU nod for Actelion's skin cancer drug Ledaga

The Swiss biotech - which already sells Ledaga (mechlorethamine or chlormethine) under the Valchlor brand in the US - notes that the European Commission cleared the drug as a topical treatment for mycosis ... Actelion acquired Valchlor in 2013 when it

Latest news

  • Actelion partners with PatientsLikeMe on blood cancer research Actelion partners with PatientsLikeMe on blood cancer research

    Mitchell Nagao, Actelion's senior director - medical head of Valchlor and Zavesca, said: “ As changes in technology, culture, and treatment affect how patients live with disease, we want measurement to evolve

  • Actelion complete Ceptaris purchase Actelion complete Ceptaris purchase

    Actelion has completed its purchase of Ceptaris Therapeutics following the approval last month of the latter's lymphoma gel product Valchlor. ... Such preparations do not undergo the same rigorous FDA review as Valchlor," he added.

  • Actelion to buy Ceptaris - if FDA backs its cancer treatment Actelion to buy Ceptaris - if FDA backs its cancer treatment

    Acquisition contingent on Valchlor approval in rare lymphoma. Actelion is set to acquire US-based biopharma Ceptaris, but only if US regulators approve Ceptaris' cancer treatment Valchlor. ... Valchlor is also under review in Europe where it is also

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics